Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Operating activities
Net income (loss)	$ 9,715	$ (10,373)	$ (1,948)
Less: gain from discontinued operations	3	2,413	6,389
Income (loss) from continuing operations	9,712	(12,786)	(8,337)
Adjustments to reconcile net income (loss) to net cash used in operating activities, including effects of business acquired:
Write-off of acquired in-process research and development	2,282	2,754	442
Non-cash change in estimated fair value of contingent liabilities	1,888	(9,142)	0
Accretion of deferred gain on sale leaseback	(1,702)	(1,702)	(21,851)
Depreciation and amortization	2,790	2,212	4,634
Non-cash lease costs	(51)	9,042	10,102
Non-cash development milestone revenue			(915)
Loss (gain) on asset write-offs	(456)	5,303	500
Realized loss (gain) on investment	6	(607)	(232)
Stock-based compensation	3,351	2,325	3,365
Deferred income taxes	(13,402)
Other	285	32	(18)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable, net	(3,915)	(375)	(618)
Inventory	1,114
Other current assets	4,864	(3,931)	(448)
Other long term assets	605	(332)	10,346
Accounts payable and accrued liabilities	(11,568)	(13,447)	(10,989)
Other liabilities	865	(715)	(2,318)
Deferred revenue	2,160	(5,938)	(14,302)
Net cash used in operating activities of continuing operations	(1,172)	(27,307)	(30,639)
Net cash provided by (used in) operating activities of discontinued operations		240	(3,162)
Net cash used in operating activities	(1,172)	(27,067)	(33,801)
Investing activities
Acquisition of Metabasis, net of cash acquired		(2,834)
Acquisition of CyDex, net of cash acquired	(32,024)
Cash acquired from acquisition of Neurogen			9,796
Payments to CVR holders	(2,875)
Acquisition of intellectual property		(1,247)
Purchases of property, equipment and building	(78)	(70)	(522)
Proceeds from sale of property, and equipment and building	530	589	108
Purchases of short-term investments	(10,000)	(35,584)	(32,806)
Proceeds from sale of short-term investments	19,346	54,040	47,761
Other, net	(31)	(354)	431
Net cash provide by (used in) investing activities of continuing operations	(25,132)	14,540	24,768
Net cash provided by investing activities of discontinued operations
Net cash provided by (used in) investing activities	(25,132)	14,540	24,768
Financing activities
Principal payments on equipment financing obligations		(91)	(473)
Proceeds from issuance of debt	30,000
Repayment of debt			(3,443)
Proceeds from issuance of common stock, net	54	23	228
Share repurchases	(55)	(91)
Net cash provided by (used in) financing activities of continuing operations	29,999	(159)	(3,688)
Net cash provided by (used in) financing activities of discontinued operations
Net cash provided by (used in) financing activities	29,999	(159)	(3,688)
Net increase (decrease) in cash and cash equivalents	3,695	(12,686)	(12,721)
Cash and cash equivalents at beginning of year	3,346	16,032	28,753
Cash and cash equivalents at end of year	7,041	3,346	16,032
Supplemental disclosure of cash flow information
Interest paid	2,463	58	270
Taxes paid	39	28	14
Proceeds received from sale of building and disbursed to Neurogen shareholders		$ 3,170
Supplemental schedule of non-cash investing and financing activities
Issuance of common stock for acquisition			8,946